{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:18:41Z","timestamp":1791296321992,"version":"4.1.0"},"reference-count":14,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,11,18]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Eliglustat tartrate is an investigational oral substrate reduction therapy for Gaucher disease type 1 that is pharmacologically distinct from intravenous enzyme replacement therapy. Eliglustat tartrate improved clinical manifestations in patients who received 50 or 100 mg twice daily for 1 year during an open-label phase 2 study (Blood. 2010;116(6):893-899). We report further improvements after 2 years of treatment in 20 patients (11 females, 9 males; mean age, 33 years) with baseline splenomegaly and thrombocytopenia and\/or anemia. Statistically significant (P &lt; .001) percentage improvements from baseline occurred in platelet count (mean \u00b1 SD, 81% \u00b1 56%), hemoglobin level (20% \u00b1 15%), spleen volume (\u221252% \u00b1 11%), and liver volume (\u221224% \u00b1 13%). Mean platelet count increased \u223c 50 000\/mm3. Mean hemoglobin level increased 2.1 g\/dL overall and 3.1 g\/dL in 10 patients with baseline anemia. Organ volume reductions were greatest in patients with severe baseline organomegaly. Seventeen (85%) patients met established therapeutic goals for \u2265 3 of the 4 parameters. Lumbar spine bone mineral density increased 7.8% \u00b1 10.6% (P = .01) and T-score 0.6 \u00b1 0.8 (P = .012), with major gains in osteoporotic and osteopenic patients. Magnetic resonance imaging assessment showed that bone marrow infiltration by Gaucher cells was decreased (8\/18 patients) or stable (10\/18 patients). No safety-related trends emerged during 2 years of treatment. This multisite, open-label, single-arm phase 2 study is registered at www.clinicaltrials.gov as NCT00358150.<\/jats:p>","DOI":"10.1182\/blood-2010-06-293902","type":"journal-article","created":{"date-parts":[[2010,8,17]],"date-time":"2010-08-17T04:49:37Z","timestamp":1282020577000},"page":"4095-4098","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":136,"title":["Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study"],"prefix":"10.1182","volume":"116","author":[{"given":"Elena","family":"Lukina","sequence":"first","affiliation":[{"name":"Hematology Research Center, Russian Academy of Medical Sciences, Moscow, Russia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Watman","sequence":"additional","affiliation":[{"name":"Hospital Ramos Mejia, Buenos Aires, Argentina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa Avila","family":"Arreguin","sequence":"additional","affiliation":[{"name":"Instituto Mexicano del Seguro Social, Hospital de Especialidades, Mexico City, Mexico;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Dragosky","sequence":"additional","affiliation":[{"name":"Instituto Argentino de Diagn\u00f3stico y Tratamiento, Buenos Aires, Argentina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Iastrebner","sequence":"additional","affiliation":[{"name":"Instituto Argentino de Diagn\u00f3stico y Tratamiento, Buenos Aires, Argentina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Rosenbaum","sequence":"additional","affiliation":[{"name":"Rambam Medical Center, Haifa, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mici","family":"Phillips","sequence":"additional","affiliation":[{"name":"Shaare Zedek Medical Center, Jerusalem, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Pastores","sequence":"additional","affiliation":[{"name":"New York University, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi S.","family":"Kamath","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel I.","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Kaper","sequence":"additional","affiliation":[{"name":"Genzyme Corporation, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejdip","family":"Singh","sequence":"additional","affiliation":[{"name":"Genzyme Corporation, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Cristina","family":"Puga","sequence":"additional","affiliation":[{"name":"Genzyme Corporation, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Judith","family":"Peterschmitt","sequence":"additional","affiliation":[{"name":"Genzyme Corporation, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111723282219500_B1","first-page":"3635","article-title":"Gaucher disease.","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"Beutler","year":"2001"},{"issue":"3","key":"2019111723282219500_B2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2007.04.001","article-title":"A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease.","volume":"91","author":"McEachern","year":"2007","journal-title":"Mol Genet Metab"},{"key":"2019111723282219500_B3","doi-asserted-by":"crossref","unstructured":"Peterschmitt MJ Burke A Blankstein L Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers [published online ahead of print October 25, 2010]. J Clin Pharmacol doi:10.1177\/0091270010372387","DOI":"10.1177\/0091270010372387"},{"issue":"6","key":"2019111723282219500_B4","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","article-title":"A Phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"key":"2019111723282219500_B5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease.","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin Hematol"},{"key":"2019111723282219500_B6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminhematol.2004.07.010","article-title":"Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients.","volume":"41","author":"Weinreb","year":"2004","journal-title":"Semin Hematol"},{"issue":"1","key":"2019111723282219500_B7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","article-title":"Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources.","volume":"122","author":"Grabowski","year":"1995","journal-title":"Ann Intern Med"},{"issue":"6","key":"2019111723282219500_B8","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1185\/030079906X104623","article-title":"Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients.","volume":"22","author":"Vom Dahl","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"2019111723282219500_B9","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1542\/peds.96.4.629","article-title":"Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase.","volume":"96","author":"Rosenthal","year":"1995","journal-title":"Pediatrics"},{"issue":"5","key":"2019111723282219500_B10","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1182\/blood-2003-11-3854","article-title":"Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy.","volume":"104","author":"Wenstrup","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2019111723282219500_B11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jocd.2007.12.007","article-title":"Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference.","volume":"11","author":"Baim","year":"2008","journal-title":"J Clin Densitom"},{"issue":"6","key":"2019111723282219500_B12","doi-asserted-by":"crossref","first-page":"802","DOI":"10.2106\/00004623-198668060-00002","article-title":"Evaluation of Gaucher disease using magnetic resonance imaging.","volume":"68","author":"Rosenthal","year":"1986","journal-title":"J Bone Joint Surg Am"},{"key":"2019111723282219500_B13","article-title":"Miglustat [package insert].","year":"2008"},{"issue":"4","key":"2019111723282219500_B14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10545-010-9095-5","article-title":"The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG).","volume":"33","author":"Cherin","year":"2010","journal-title":"J Inherit Metab Dis"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/116\/20\/4095\/1489157\/zh804610004095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/116\/20\/4095\/1489157\/zh804610004095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T21:59:28Z","timestamp":1685743168000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/116\/20\/4095\/28081\/Improvement-in-hematological-visceral-and-skeletal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,18]]},"references-count":14,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2010,11,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2010-06-293902","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,18]]}}}